References
- Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, et al. 2022. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guidelines update. J Clin Oncol. 40(16):1816–1837. Published online April 19, doi: 10.1200/JCO.22.00069
- Gradishar WJ, Moran MS, Abraham J, et al. 2023. NCCN clinical practice guidelines in oncology. Breast Cancer. Version 4.2034-March 23, nccn.org
- Hayes DF. 2020. Defining clinical utility of tumor of tumor biomarker tests: A clinician’s viewpoint. J Clin Oncol. 39(3):238–248. Published online Dec 16, doi: 10.1200/JCO.20.01572
- Holm M, Tjønneland A, Balslev E, Kroman N. 2014. Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies. Breast Cancer Res Treat. 146(3):461–475. doi: 10.1007/s10549-014-3045-0
- https://www.fda.gov/news-events/press-announcements/fda-updates-mammography-regulations-require-reporting-breast-density-information-and-enhance.
- Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, et al. 2021. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 385(25):2336–2347. doi: 10.1056/NEJMoa2108873
- Karsten M, Stempel M, Radosa J, Patil S, King TA. 2016. Oncotype DX in bilateral synchronous primary invasive breast cancer. Ann Surg Oncol. 23(2):471–476. doi: 10.1245/s10434-015-4841-4